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Abstract
Influenza vaccination is the primary approach to prevent influenza annually. WHO/CDC recommendations prioritize
vaccinations mainly on the basis of age and co-morbidities, but have never considered influenza infection history of
individuals for vaccination targeting. We evaluated such influenza vaccination policies through small-world contact
networks simulations. Further, to verify our findings we analyzed, independently, large-scale empirical data of influenza
diagnosis from the two largest Health Maintenance Organizations in Israel, together covering more than 74% of the Israeli
population. These longitudinal individual-level data include about nine million cases of influenza diagnosed over a decade.
Through contact network epidemiology simulations, we found that individuals previously infected with influenza have a
disproportionate probability of being highly connected within networks and transmitting to others. Therefore, we showed
that prioritizing those previously infected for vaccination would be more effective than a random vaccination policy in
reducing infection. The effectiveness of such a policy is robust over a range of epidemiological assumptions, including cross-
reactivity between influenza strains conferring partial protection as high as 55%. Empirically, our analysis of the medical
records confirms that in every age group, case definition for influenza, clinical diagnosis, and year tested, patients infected
in the year prior had a substantially higher risk of becoming infected in the subsequent year. Accordingly, considering
individual infection history in targeting and promoting influenza vaccination is predicted to be a highly effective
supplement to the current policy. Our approach can also be generalized for other infectious disease, computer viruses, or
ecological networks.
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Introduction
Influenza has a long history of causing substantial morbidity,
mortality and economic losses annually [1–3]. In Israel, influenza
is responsible for about 801,200 reported infections (around 10%
of the population), 4130 hospitalizations, 1140 deaths, and
economic costs of 261 million dollars [3,4], while in the US,
influenza is responsible for 610,600 life years lost and economic
loss of $87.1 billion annually [1]. Influenza vaccination is the
primary approach to reduce the disease burden and is important
not only for those vaccinated, but also to reduce transmission [2].
Recommendations by the World Health Organizations (WHO)
[5], the U.S. Center for Disease Control and Prevention (CDC)
[2], as well as the Israeli Ministry of Health have prioritized
vaccination based on age, profession, and co-morbidities. How-
ever, these recommendations have not considered individual
influenza infection history as an indication of future risk that can
be used to supplement current policies.
An individual’s infection risk is governed by their contacts as
manifested by their social interactions. A contact network model
captures the patterns of interactions that expose individuals to
potential transmission. In the context of contact network
epidemiology, centrals, individuals characterized by higher con-
nectivity than average, are more likely both to become infected
and to transmit infection [6,7]. Thus, prioritizing the vaccination
of centrals could be effective in curtailing influenza transmission by
reducing the network connectivity. However, identifying centrals is
challenging [8], because the contact network is generally
unknown.
One study [6] offered a novel way to reach the centrals in a
network by randomly choosing individuals and asking them to
deliver a vaccination dose to one of their contacts, an approach
known as the ‘acquaintance immunization strategy’, suggests an indirect
way to locate the centrals. Although this approach is an effective
way to curtail transmission in both computer and population
networks, it would be challenging to implement such a policy in
the case of influenza vaccination.
In the current study we offer a practical way to devise a
vaccination policy using the simple logic of targeting previous
influenza patients. We propose that even in the absence of
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influenza infection and can thus be identified as being dispropor-
tionately represented in the pool of individuals who were
previously infected. Further, in addition to social interaction, a
variety of factors, such as genetics, co-morbidities, demographics,
and epidemiological characteristics [2], may affect the risk and
severity of infection, and remain relatively invariable over time.
Regardless of whether individuals are predisposed to infection
because of these factors or contact connectedness, they can be
identified through previous infection. This approach is more
straightforward than attempting to target individuals based on all
possible risk factors, particularly as some risk factors may be
unknown, difficult to identify or politically challenging to
implement. Although the effectiveness of a policy that targets
those previously infected initially seems to be counter-intuitive,
since previously infected are likely to have partial protection
against subsequent infection due to cross-reactivate antibodies [9],
we found that previously infected individuals are much more likely
to be infected even when taking into account biologically realistic
rates of cross-reactivity [10].
Our findings are based on contact network epidemiology
simulations and confirmed by empirical clinical data provided by
the two largest Health Maintenance Organizations (HMOs) in
Israel, covering more than 74% of the Israeli population. Our
study is the first to address the interplay among previous infection
history, immunological cross-reactivity, and social behavior as the
basis for an innovative yet feasible supplement to the current
influenza vaccination policies.
Methods
Ethics statement
The surveillance data were analyzed anonymously, and
approved to be used by the Clalit health services sub-Helsinky
institutional review board, signed and approved by Dr. Eitan
Wertheim, protocol number 127/2012.
Contact network simulations
Our simulations were applied to an epidemiological contact
network based on the Portland population [11]. The Portland
contact network derives from detailed microscopic simulation-
based modeling and integration techniques performed by the
Network Dynamic and Simulation Science Laboratory (NDSSL)
at Virginia Tech with the purpose of creating a contact network
reflecting an urban population [11]. The network includes
1,575,861 nodes, each of which represent an individual and
19,681,820 edges, each of which represents a contact between
individuals.
To determine the robustness of our results, we validated our
findings on three alternative small-world [12] scale-free networks:
the Brightkite location-based network, the Gowalla location-based
network, and the Baraba ´si algorithm based network [13–15].
These networks vary in terms of the number of contacts, clustering
coefficients, and the node-to-node distance [12]. The Brightkite
location-based network is based on service providers where users
share their locations by checking-in. The network was generated
by the Stanford Network Analysis Project using their public
Application Programming Interface, which consists of 58,228
nodes and 214,078 edges [16]. The Gowalla location-based
contact network is a website where users share their locations by
checking-in. The network was collected by the Stanford Network
Analysis. It consists of 196,591 nodes and 950,327 edges [13]. We
also created a network with 100,000 nodes and 400,000 edges
according to the Baraba ´si algorithm [14].
To evaluate centrality for each node in the networks, we
calculated two common measures: number of contacts and K-shell
decomposition values (K-shell) (Figure S1). Compared with the
straightforward number of contacts measure, K-shell also take into
account the global connectivity of the nodes to which a node is
connected [17,18].
We used the Susceptible-Infectious-Recovered (SIR) compart-
mental model [19] to evaluate disease spread within the networks.
According to each network configuration, an individual may infect
only susceptible neighbors (i.e., nodes with whom they have edges).
Given that not all individuals will be susceptible in the beginning
of each season [10,20,21], we parameterized transmissibility using
the effective reproductive number, Re [21–23], defined as the
average number of secondary infections resulting from each
infective person [19] (Table 1). Protection following infection may
last longer than a year [10] due to cross-reactivity between years.
We considered the entire possible range of cross-reactivity from 0
to 100%, where 0% corresponds to no immunological protection
and 100% corresponds to full protection acquired from influenza
infection in the prior year. Depending on vaccine efficacy
(Table 1), we assume that a proportion of individuals who are
vaccinated are protected for one season [24].
We ran over one million simulations drawing parameter values
from distributions that span a biologically realistic range (Table 1),
as well as different vaccination rates and efficacies (Text S1). To
determine whether previously infected individuals are more likely
to be centrals, we evaluated the decile of the centrality score for
each node in the network (based on the two measurements of
centrality) and the risk ratio of becoming infected for a range of
reproductive ratios and for different levels of cross-reactivity
compared with the risk of a random individual. In each iteration of
the simulation, we ran two successive influenza seasons. In the first
season, we randomly vaccinated 0–40% of the population. In the
second season of each simulation, we considered three policies: a
Author Summary
WHO/CDC recommendations prioritize influenza vaccina-
tions primarily on the basis of age co-morbidities, but have
never considered targeting vaccination for individuals
previously infected with influenza. An individual’s infection
risk is governed by his or her contacts as manifested by his
or her social interactions. Thus, through contact network
simulations that capture contact patterns, we show here
that individuals previously infected with influenza have a
disproportionate probability of being highly connected
within networks and thus serve as the super-spreaders.
Accordingly, targeting them is effective in curtailing
transmission. In addition to social interaction, a variety of
factors, including genetics, co-morbidities, demographics,
and epidemiological characteristics, may affect the risk and
severity of influenza infection. Regardless of whether
individuals are predisposed to infection because of these
factors, or social interactions, we show that they can be
identified through previous infection. Empirically, our
analysis of medical records of influenza diagnosed in both
hospitals and clinics confirms that in every age group, case
definition for influenza, clinical diagnosis, and year tested,
patients infected in the year prior had a substantially
higher risk of becoming infected in the subsequent year.
Thus, considering individual infection history in targeting
and promoting influenza vaccination is predicted to be a
highly effective supplement to the current prioritizations
as it focuses on people with greater risk to become
infected and transmit.
Last Season’s Patients for Influenza Vaccination
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tion policy (AIP), which targets the acquaintances of a random
node [6], and a vaccination policy prioritizing those who were
infected in the previous season, Previously Infected Policy (PIP).
For the PIP strategy, we assumed previously infected individuals
are vaccinated first. If any vaccine doses remain after those
prioritized have been vaccinated, the remaining doses are
randomly distributed to the rest of the population.
Empirical demonstration
Our primary data were provided by Clalit Health Services and
Maccabi Health Services and included demographic, socio-
economic, and ethnic data [25]. Clalit is the largest HMO in
Israel, with membership varying between 3.47–3.72 million, and
constituting about 53% of the Israeli population during the 2003–
2012 the study period.
The Clalit dataset includes codes of the diagnosis recorded by
the physicians in clinics according to the ICD9 protocol (codes 487
for ‘influenza’ and 465 for ‘acute upper respiratory infections of
multiple or unspecified sites’) as well as hospitalizations due to
influenza or pneumonia (ICD9, 486 ‘pneumonia organism
unspecified’ as well as codes 487, 465). Maccabi is the second
largest HMO in Israel with 1.4–1.8 million members, constituting
about 23% of the Israeli population, during the study period.
Their records include full datasets of 12 years from September
1998 to April 2010 with 380,000 records. The data included
influenza cases diagnosed in clinics according to the ICD10
protocol (code J11). Our case definition for influenza-like-illness
(ILI) in both of the health maintenance organizations is detailed in
Text S2.
As influenza infection rates depend on age, we stratified our
data analysis by: 0–5, 6–15, 16–25, 26–35, 36–49, 50+. This
division also facilitates evaluating the age-specific prioritization of
the recommendations of the U.S. CDC as well as the Israeli
Health Ministry which currently focus on ages 0–5 and individuals
above age 50. In addition, we considered the relative risk of age
group 25–35 which, along with children, are disproportionately
responsible for transmission [26].
Rather than a case of influenza, an ILI infection might indicate
elevated risk for influenza, because transmission routes of many
upper respiratory diseases are similar. Thus, an ILI might serve as
a predictor of elevated risk for both ILI and actual influenza. For
each age group, in both HMOs, we calculated the relative risk of
infection for those previously diagnosed with ILI compared with
others in the same age group that had not been diagnosed in prior
season.
In the Clalit dataset we stratified our ten seasons of data into
eleven pairs of two consecutive seasons and calculated the risk of
outpatient influenza in season i for influenza outpatient patients
diagnosed in season i21, the risk of outpatient influenza in season i
for patients hospitalized in season i21, the risk of becoming
hospitalized with influenza in season i for outpatient patients
diagnosed in season i21, and the risk of becoming hospitalized
with influenza in season i for patients hospitalized in season i21.
In the Maccabi dataset, we stratified our twelve seasons of data
into eleven pairs of two consecutive seasons and calculated the risk
of outpatient influenza in season i for influenza outpatient patients
diagnosed in season i21 (Text S2).
Not all influenza patients seek medical treatment [1,27], and
some people might have higher tendency to seek medical
treatment when infected with influenza than others, potentially
leading to an overestimation relative risks. In addition, individuals
are likely to visit the same physician when infected with influenza,
and the latter might not diagnosis the infection as ILI. Thus, we
compared evaluations of the policies under the conservative
assumption that individuals can be divided into those that either
seek medical treatment when infected, or not seek medical
treatment. Under this conservative assumption, we calculated an
adjusted relative risk of outpatient infection by removing in each
age group members who were never an outpatient along the entire
period tested.
Results
The risk of future influenza infections for individuals is
determined by the interplay between two countering factors:
social interaction, which governs exposure probability, and cross-
reactivity protection acquired from previous infection. We found
that these factors will affect: 1) the conditions under which central
individuals have a higher risk of infection than non-centrals, 2) the
conditions under which individuals infected in the prior season
have a higher risk to become infected in a succeeding season, and,
consequently, 3) the conditions in which the targeting of last
season’s patients for influenza vaccination will serve as an effective
policy to decrease morbidity. Overall, our analysis demonstrates
that social interaction dominated in determining the overall
effectiveness of targeting influenza vaccination to previously
infected individuals in vast ranges of realistic conditions, as
elaborated below.
Our contact network simulations reveal that individuals infected
with influenza in the prior year have a greater probability of being
more central than others. This finding is robust to the two different
measurements of centrality considered (Figures 1 and S2), and
over the range of biologically realistic epidemiological parameters
for influenza (Table 1). The results were more sensitive to the
initial proportion of susceptibles. Specifically, the greater the cross-
reactivity and attack rate are in the previous season, the lower is
Table 1. Parameter ranges and values for numerical simulations.
Symbol Definition Distribution/range checked References
i0 Initial infection fraction Uniform(0.0001,0.001) [23]
Re Effective reproductive ratio 1.2–1.6 [23,26,31]
V Vaccination rate 0–0.4 [35]
R Vaccination efficacy 0.5–0.8 [2]
D Infection duration (in days) Normal(3.8, 2) [22,36]
h Cross-reactivity rate 0–1
T Daily susceptibility rate between two neighbors Uniform (0.012,0.087) Supplements
doi:10.1371/journal.pcbi.1003643.t001
Last Season’s Patients for Influenza Vaccination
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the network. For example, in the Portland network, we found that
individuals with higher K-shell values or higher number of contacts
than others have a higher risk of infection when cross-reactivity
ranges between 0–60%. For cross-reactivity higher than 60%, and
particularly for the upper estimates of influenza transmissibility (i.e.,
Re$1.4), individuals in the ninth or tenth decile with the highest K-
shell value or number of contacts are less likely to get infected
relative to individuals in the fifth decile, because the former were
more likely to have cross-protection from previous exposure.
Nevertheless, even in this case, individuals who have a centrality
score above the median have a higher risk for re-infection than
individuals below the median (Figures 1 and 2). Collectively,
centrals are disproportionately represented in those who were
previously infected even when cross-reactivity reached 80%.
For seasons between which there is no cross-reactivity, we
showed analytically that prior influenza patients have a higher risk
of infection in the succeeding season (text S1). Consistent with this
analytical finding, our simulations on the Portland network also
demonstrate that when there is no cross-reactivity, the relative risk
of previous patients ranges from 2.3–3.1 compared to individuals
not infected in the prior season. However, this risk can also fall
below one in cross-reactivity rates above 60% (Figure S3).
We compared three policies: a Random Vaccination Policy
(RVP), the acquaintance immunization policy (AIP), and a
vaccination policy prioritizing those who were infected in the
previous season, Previously Infected Policy (PIP) (see methods).
Overall, in the Portland network, results demonstrate that PIP is
more effective than AIP in reducing morbidity rates even in cases
where cross-reactivity is as high as 36–72%. PIP is also more
preferable than RVP even in cases where cross-reactivity is as high
as 57–78% (Figures 3, Figure S4 and Figure S5). For example,
when cross-reactivity of 40% has been observed and 15% are
vaccinated the mean risk of infection would be 14%, 11.5% and
5.6% for RVP, AIP and PIP, respectively; whereas when 30% are
vaccinated the mean risk would be 8.6%, 4.6%, and 3.6% for
RVP, AIP and PIP, respectively.
The variability observed in our simulations (Figure 3, Figure S4
and Figure S5) arises from the sensitivity of PIP to two drivers. The
first driver is the vaccination coverage in the previous season or
infected in the previous season and who remained protected due to
cross-reactivity as those individuals cannot be detected by our
policy. The second driver is the incidence in the previous season. If
the prior incidence is relatively low, all of those who had been
infected in the prior year would be vaccinated in the subsequent
year, but the remaining doses will be randomly distributed to the
Figure 1. The relative risk of infection given parameters of centrality. The mean and 95% confidence interval of relative risk of infection for
an individual compared to the rest of the population, given his/her K-shell (panels A and B), and number of contacts (panels C and D) for cross-
reactivity levels of 0% (panels A and C) and 80% (panels B and D) for effective reproductive number, Re=1.2 (dotted red), 1.4 (dashed blue) and 1.6
(dot-dashed green). A relative risk above one represents higher risk of infection, compared with the rest of the population.
doi:10.1371/journal.pcbi.1003643.g001
Last Season’s Patients for Influenza Vaccination
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RVP.
To verify the robustness of our results, we determined the
effectiveness of PIP for four networks across a range of biologically
realistic epidemiological parameters for influenza (Table 1). PIP
was found to be more effective than RVP when cross-reactivity was
as high as 57–75% in the Portland Network, 55–80% in the
Baraba ´si algorithm-based network, 80–95% in the Brightkite
Network, and 75–90% in the Gowalla Network. In comparison
with AIP, PIP was effective in lower values of cross-reactivity levels,
ranged from 35–72.5% in Portland Network, 0–40% Brightkite
Network, and 0–40% in the Gowalla Network (Figure 3). PIP was
less effective than AIP in the Baraba ´si algorithm based network,
possibly as a result of the homogeneity of K-shell values among
nodes in this network (Figures S1).
Empirical demonstration
Given that influenza attack rate ranges epidemiologically
between 5–15% [2], our case definition for influenza may be
under-reported in the Maccabi dataset and over-reported in the
Figure 2. Mean risk of infection following vaccination. The mean risk of infection evaluated over the parameters ranges in Table 1 for RVP
(dashed blue), AIP (dashed-doted red), PIP (dashed green), as well as no vaccination (solid black), for cross-reactivity levels of A and B) 0%, C and D)
40%, E and F) 60% G and H) 80%. In the second season, for RVP, AIP and PIP strategies, vaccination coverage for A, C, E and G) 15% and for B, D, F and
H) 30%, and vaccine efficacy of 75%. PIP is preferable than RVP in reducing morbidity for panels A–F, and more preferable than AIP for panels A–D. As
explained in the main text, the risk of infection decreases as the cross-reactivity increases.
doi:10.1371/journal.pcbi.1003643.g002
Last Season’s Patients for Influenza Vaccination
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medical records showed that patients diagnosed with ILI in the
previous season have a substantially higher risk to be diagnosed
with ILI in the succeeding year (Table 2). Excepting children
below five who had a lower risk of being hospitalized, diagnosed
with outpatient influenza in the season prior, our results were
robust for both HMOs, for each age group and for almost every
year tested. For example, in the Maccabi dataset within the age
group of 35–49, only 1.45% of the population was outpatient ILI.
However, for individuals within this age group who were
diagnosed in the previous year, the risk of becoming infected in
the subsequent year was 11.35%. In the Clalit dataset, within the
age group 35–49, 9.36% were outpatient ILI. The risk was about
four times higher in patients who were outpatient ILI, and two fold
in patients previously hospitalized compared with patients who did
not seek medical treatment of ILI in the year prior (Table 2).
Even when we calculated an adjusted relative risk of outpatient
influenza by considering only members who were diagnosed with
outpatient influenza at least once in the study period (i.e. 2003–
2012 in Clalit dataset and 1998–2010 in Maccabi dataset),
the relative risk for individuals previously outpatient was still
higher than one in each age group (Table 2). This finding
demonstrates that, in addition to age, an individual’s infection
history plays an important role in determining their subsequent
risk of infection.
Discussion
Our work shows that considering individual infection history in
targeting and promoting influenza vaccination would be an
effective supplement to the current policy which prioritizes
individuals on the basis of age and co-morbidities. Our findings
highlight the fundamental role that an individual’s social behavior
plays in disease transmission [28], and reveals that in the interplay
between cross-reactivity and individual risk factors the latter
dominates in determining the overall effectiveness of targeting
influenza vaccination to individuals infected in the prior season.
Our simulations demonstrate that targeting individuals previ-
ously diagnosed with influenza can be effective even if cross-
reactivity is as high as 55–80%. Empirical studies suggest that
cross-reactivity for a specific type of influenza is typically below or
within this range [10]. Additionally, there can be two or three
sub-types of influenza circulating within a single season [29] with
dominance shifting among sub-types between successive years.
Surveillance systems monitor reporting rates rather than actual
prevalence, and thus also include misdiagnoses. Nonetheless, ILI
diagnoses, even if from a different etiology, might indicate elevated
risk of future infection with influenza, because transmission routes
and associated risk factors of many upper respiratory diseases are
similar. Given that respiratory infections other than influenza will
not elicit cross-reactive antibodies, these misdiagnosed individuals
may be at even higher risk for future influenza infection than those
who were previously infected with influenza. To evaluate the
increased risk of those who were previously infected with influenza
versus other respiratory infections, future research should stratify
between clinical diagnosis and laboratory confirmation.
While social interactions modeled in our contact network
simulations are fundamental to influenza transmission, other
factors including genetics, co-morbidities, and demography,
contribute to determine risk for an individual. Similar to social
tendencies, these other factors will also remain relatively invariable
for an individual from year to year. Consequently, previous,
current, and future infection risk can be even more effectively
predicted by prior infection than what we conservatively estimated
from social interaction alone.
If PIP is implemented every influenza season, individuals with
high connectivity might be targeted in the first year, and therefore
will reduce their risk of infection in the subsequent year. However,
Figure 3. Mean indifference curves for PIP vs. RVP and PIP vs. AIP. The curves are shown as a function of the effective reproductive number
and cross-reactivity for A) the Portland Network B) Baraba ´si algorithm-based network C) Brightkite Network D) Gowalla Network. Above each curve,
RVP/AIP is the recommended policy, whereas below the curve, PIP is recommended.
doi:10.1371/journal.pcbi.1003643.g003
Last Season’s Patients for Influenza Vaccination
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PIP policy, they will be less likely to be infected and subsequently
targeted. Thus, future studies could evaluate the marginal benefit
of considering infection and vaccination history of individuals over
several seasons relative to the prior season alone in determining
vaccine targets.
Targeting previously infected individuals is a relatively straight-
forward approach to implement in an HMO system with
electronic medical records. For instances, individuals previously
infected could be flagged within the electronic records for
vaccination targeting by mailing pamphlets, telephone reminders
or physician recommendations, practices shown to be effective in
promoting influenza vaccination [2]. The suggested policy could
reach several sub-populations, such as those based on socio-
economic status and ethnicity, that correlated with vaccine uptake
and infection rates [30], but which have not been prioritized in the
past due to ethical or political reasons. Furthermore, a high level of
public adherence to this targeted strategy is likely to be achievable,
given that individuals who were recently ill with influenza will
probably be responsive to strategies that reduce their personal risk,
as has been shown to be a primary motivator in vaccination
decisions [23,31,32].
We demonstrated the potential benefit of targeting last
season’s patients for influenza, but such policy may also be
applicable to other diseases including respiratory syncytial virus,
pneumococcal infections and malaria, for which re-infection is
common. Our approach may be generalized to networks outside
the public health field, such as ecology and computer science.
For example, our approach may determine which computers
should be prioritized for antivirus software installations. In fact,
a previous study on computer networks showed that computers
that were attacked in one simulation run are most prone to
attack in other simulation runs [33]. The authors even suggested
little variation in the number of reinfections experienced by the
same computer in different simulation studies, making our
approach likely to be highly effective. In another example, our
approach may also be helpful in ecological networks to identify
and invest efforts to protect species with most essential to
community stability [34].
In summary, we modeled the interplay among previous
infection history, immunological cross-reactivity, and social
behavior as the basis to generate an innovative influenza
vaccination policy. Through contact network simulations we
showed that individuals infected in the year prior have higher
connectivity in the network, and subsequently increased risk of
infection and transmission. Empirically, our analysis of the
medical records confirms that in every age group, case
definition for influenza, clinical diagnosis and year tested,
patients infected in the year prior had a substantially higher
risk of becoming infected in the subsequent year. Accordingly,
the targeting of individuals infected in the prior year is
predicted to be a highly effective supplement to the current
policy.
Supporting Information
Figure S1 Distribution of measurements of centrality.
The distribution of 1) Number of contacts, and 2) K-shell is shown
for A) the Portland Network, B) Brightkite Network, C) Gowalla
Network, D) Baraba ´si Algorithm-Based Network.
(TIF)
Figure S2 Relative risk of infection given parameters of
centrality. The mean and 95% confidence interval of the relative
risk of infection for an individual compared to the rest of the
population, given his/her K-shell (panels A and B), and number of
contacts (panels C and D) for cross-reactivity levels of A) 20% B)
40% C) 60% for effective reproductive number, Re=1.2 (dotted
red), 1.4 (dashed blue) and 1.6 (dot-dashed green). A relative risk
above one represents higher risk of infection, compared with the
rest of the population. The figure complements Figure 1.
(TIF)
Figure S3 Effects of previous illness on future infection
proportion. The mean and 95% confidence interval of the
relative risk of infection in individuals previously infected versus
individuals not previously infected depending on Re and cross-
reactivity. The black line represents relative risk equal to one.
(TIF)
Figure S4 Boxplot risk of infection following vaccina-
tion. Box-and-Whisker plots of the difference between the risk of
infections for RVP and PIP, and AIP and PIP, over the parameters
ranges in Table 1, for cross-reactivity of A) 0%, B) 40%, C) 60%,
and D) 80%, assuming vaccination coverage of 15% and vaccine
efficacy of 75%. This figure corresponds to Figure 2 panels A, C,
E, and F.
(TIF)
Figure S5 Boxplot risk of infection following vaccina-
tion. Box-and-Whisker plots of the difference between the risk of
infections for RVP and PIP, and AIP and PIP, over the parameters
ranges in Table 1, for cross-reactivity of A) 0%, B) 40%, C) 60%,
and D) 80%, assuming vaccination coverage of 30% and vaccine
efficacy of 75%. This figure corresponds to Figure 2 panels B, D,
F, and G.
(TIF)
Figure S6 Frequency of ILI diagnosis. The right axis refers
to influenza and pneumonia diagnosed in hospitals. The left axis
refers to influenza diagnosis.
(TIF)
Text S1 Supporting information for contact network
analysis.
(DOCX)
Text S2 Supporting information for data analysis.
(DOCX)
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